If you read the Tweet he was restating what NWBO reported in the EU clinical trials registry -- that the OS metric was NOT using the the internal control which they replace with the external controls from other GBM trials. That's it.
That is much different that the May 10, 2022 that was based on the NYAS TLD. and the complete protocol, endpoints and SAP announcement with the TLD.